David K. Lam


  • Yale University, B.A. 1997, summa cum laude
  • Yale Law School, J.D. 2000 (Managing Editor, Yale Law Journal and Articles Editor, Yale Journal on Regulation)


Honorable José A. Cabranes, United States Court of Appeals, Second Circuit, 2000 – 2001

David K. Lam

David K. Lam is a corporate partner at Wachtell, Lipton, Rosen & Katz.  He focuses on mergers and acquisitions, securities transactions and corporate governance.  His practice has included a wide range of matters, including public and private acquisitions and divestitures, domestic and international transactions, carve-out IPOs, spin-offs, split-offs, joint venture transactions and private equity transactions.  He also advises numerous companies on takeover defenses, proxy contests and corporate governance matters.

David was selected by The American Lawyer as a “Dealmaker of the Year” for 2012 and for 2015, and by AmLaw Daily as a “Dealmaker of the Week” in 2015.  He is also recognized as one of the 500 leading lawyers in America by Lawdragon, and listed as a Super Lawyer in the area of mergers and acquisitions by Super Lawyers magazine.

David received his B.A. (economics and molecular biophysics & biochemistry) summa cum laude from Yale University, where he was awarded the Arthur Twining Hadley Prize and Russell Henry Chittenden Prize for the highest GPA.  He received his J.D. from Yale Law School, where he served as managing editor of the Yale Law Journal and articles editor of the Yale Journal on Regulation. Upon graduation from law school, Mr. Lam served as a law clerk to the Honorable José A. Cabranes of the U.S. Court of Appeals for the Second Circuit.

He has represented clients in a variety of industries, including:


Health Care/Pharmaceuticals

  • Pfizer in its $44 billion acquisition of Seagen, its $48 billion combination of Upjohn and Mylan to form Viatris, its consumer joint venture transaction with GlaxoSmithKline to form Haleon, its $11.4 billion acquisition of Array BioPharma, its $5.2 billion acquisition of Anacor Pharmaceuticals and its agreed $160 billion acquisition of Allergan plc
  • AbbVie in its $10.1 billion acquisition of ImmunoGen and in its $21 billion acquisition of Pharmacyclics
  • Becton Dickinson in its spin-off of its diabetes care business, Embecta
  • Celgene in its agreed $98 billion merger with Bristol-Myers Squibb
  • C.R. Bard in its $24 billion merger with Becton Dickinson
  • Abbott Laboratories in its $25 billion acquisition of St. Jude Medical, its $4.3 billion sale of its vision care business to Johnson & Johnson and its $55 billion spin-off of AbbVie
  • CareFusion in its $12.2 billion merger with Becton Dickinson
  • GlaxoSmithKline in its unsolicited offer and $3.6 billion acquisition of Human Genome Sciences
  • The Wyeth board of directors in its $68 billion merger with Pfizer
  • Cardinal Health in its $1.9 billion acquisition of Cordis from Johnson & Johnson, its joint venture transaction with CVS Caremark, its $2.1 billion acquisition of Assuramed, its $1.3 billion acquisition of Kinray, its $1.5 billion acquisition of VIASYS Healthcare, its $3.3 billion sale of its Pharmacology Technology Business to an affiliate of the Blackstone Group, its acquisition of P4 Healthcare Solutions, and in its $4.1 billion spin-off of CareFusion Corporation
  • Sanofi in its successful €47.8 billion hostile exchange offer for Aventis


Financial Services

  • Nasdaq in its $10.5 billion acquisition of Adenza, its $2.75 billion acquisition of Verafin, its $1.1 billion acquisition of International Securities Exchange from Deutsche Börse and in its $705 million acquisition of eVestment
  • American International Group in its $2.985 billion sale of ValidusRe to RenaissanceRe Holdings, its $2.2 billion sale of an equity stake in Corebridge to Blackstone and in the initial public offering of Corebridge
  • BGC Partners in its reorganization into a simplified corporation, its successful hostile acquisition of GFI Group, its $650 million sale of Trayport to Intercontinental Exchange, its $1.234 billion sale of its electronic trading business in U.S. Treasury securities to The NASDAQ OMX Group, Inc. and in its $1.4 billion reorganization and merger with eSpeed
  • New York Stock Exchange in its agreed $23.4 billion cross-border combination with Deutsche Börse, its $10 billion cross-border combination with Euronext N.V. and its merger with Archipelago
  • MetLife in the sale of its depositary business to GE Capital Retail Bank, its $1.6 billion split-off of its interest in Reinsurance Group of America and its sale of State Street Research & Management Company to BlackRock
  • Warburg Pincus in its purchase and sale of equity in Primerica from Citigroup
  • Lazard in connection with its IPO and related restructuring transactions
  • JPMorgan Chase & Co. in its acquisition of the banking business of The Bank of New York in exchange for JPMorgan Chase’s corporate trust business, and in the restructuring of its joint venture with First Data Corporation
  • Bank of America in its $21 billion acquisition of ABN Amro’s LaSalle Bank
  • Golden West Financial in its $25.5 billion sale to Wachovia



  • Seventy Seven Energy Inc. in its $2.1 billion sale to Patterson-UTI Energy
  • Energy Transfer Equity in its agreed $37.7 billion combination with The Williams Companies
  • Atlas Pipeline Partners and Atlas Energy in their $7.7 billion sale to Targa Resources Partners and Targa Resources Corp
  • Berry Petroleum in its $2.5 billion sale to LINN Energy and LinnCo
  • Sunoco in its $5.3 billion sale to Energy Transfer Partners and in its IPO and spin-off of SunCoke Energy, a $1.2 billion company
  • Atlas Energy in its $4.3 billion sale to Chevron, its $1.7 billion joint venture with Reliance Industries, and in the formation of its master limited partnership, Atlas Resource Partners
  • Acciona in its €43.7 billion acquisition with Enel of Endesa



  • Johnson Controls in its $16.5 billion merger with Tyco International, its spin-off of Adient, its automotive business, its $1.48 billion sale of its global workplace solutions business to CBRE Group, and its $965 million sale of its automotive electronics business to Gentex and Visteon
  • Rayonier in its $656 million acquisition of Pope Resources and its spin-off of its performance fibers business, Rayonier Advanced Materials
  • Rayonier Advanced Materials in its $807 million acquisition of Tembec
  • XPO Logistics in its $652 million acquisition of New Breed and in its $335 million acquisition of Pacer International


Real Estate

  • Regency Centers in its $1.4 billion acquisition of Urstadt Biddle Properties
  • Newmark Group in its initial public offering and spin-off from BGC Partners
  • Washington Prime Group in its $4.3 billion acquisition of Glimcher Realty Trust
  • AMB Property Corporation in its $15 billion merger with ProLogis
  • Sunrise Senior Living in its $3.4 billion sale to Health Care REIT
  • The Mills Corporation in its $7.8 billion sale to Simon Property Group and Farallon Capital



  • T-Mobile USA and Deutsche Telekom in the agreed $146 billion all-stock combination of T-Mobile and Sprint
  • Monsanto in its $66 billion sale to Bayer

Select Publications